NeuroPace (NASDAQ:NPCE – Get Free Report) had its price target decreased by Cantor Fitzgerald from $21.00 to $12.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price target would indicate a potential upside of 58.73% from the stock’s previous close.
Several other research analysts have also weighed in on NPCE. Weiss Ratings lowered NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. HC Wainwright decreased their target price on shares of NeuroPace from $20.00 to $12.00 and set a “buy” rating for the company in a research note on Monday. Wall Street Zen cut shares of NeuroPace from a “hold” rating to a “sell” rating in a research note on Saturday. Raymond James Financial set a $21.00 price target on shares of NeuroPace in a research note on Tuesday, September 15th. Finally, Wells Fargo & Company cut shares of NeuroPace from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $19.00 to $9.00 in a report on Friday. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, NeuroPace has an average rating of “Hold” and an average price target of $14.22.
Check Out Our Latest Report on NPCE
NeuroPace Stock Performance
Shares of NASDAQ NPCE opened at $7.56 on Friday. The stock has a 50 day moving average price of $13.21 and a 200 day moving average price of $14.75. NeuroPace has a 52 week low of $5.46 and a 52 week high of $19.60. The company has a debt-to-equity ratio of 5.15, a quick ratio of 4.09 and a current ratio of 5.26. The stock has a market capitalization of $259.49 million, a PE ratio of -13.50 and a beta of 1.98.
Institutional Trading of NeuroPace
Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in shares of NeuroPace in the second quarter valued at approximately $41,000. Algert Global LLC boosted its position in NeuroPace by 2.9% in the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock worth $2,936,000 after purchasing an additional 5,218 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in NeuroPace in the second quarter worth $157,000. Entropy Technologies LP bought a new position in NeuroPace in the 3rd quarter valued at $146,000. Finally, Lazard Asset Management LLC grew its stake in NeuroPace by 9.8% in the 1st quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock valued at $1,635,000 after purchasing an additional 11,078 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.
NeuroPace Company Profile
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
See Also
- Five stocks we like better than NeuroPace
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
